About RDPAC
Established in 1999, the R&D-Based Pharmaceutical Association Committee (RDPAC), representing 47 leading multinational pharmaceutical companies with R&D capabilities, is a committee under the China Association of Enterprises with Foreign Investment (CAEFI), which in turn reports to the Ministry of Commerce of the People's Republic of China.
Through collaboration with key stakeholders to promote international cooperation and bridge communications between the government and the industry, RDPAC advocates sustainable policies that incentivize pharmaceutical innovation to ensure novel medicines benefit Chinese patients as early and as extensively as possible. It is dedicated to elevating China's pharmaceutical innovation ecosystem to foster higher-quality industry development, and to contributing to ‘Healthy China’ to improve the health and well-being of people in China.
By 2023，RDPAC member companies have established 43 factories and 29 R&D centers in China. From 1999 to 2023, RDPAC member companies have introduced over 800 innovative drugs to the Chinese market.
VISION
HEALTHIER CHINA THROUGH INNOVATION
To be a valued partner in delivering the “Healthy China” goal to improve the health and quality of life of people in China:
• Provide high-quality/ innovative healthcare products and services in a socially responsible and commercially viable manner;
• Commit to securing patients timely access to innovative & high quality drugs;
• Achieve the highest standard of integrity for ethical research and business practice;
• Contribute to the growth of the biopharmaceutical sector in China;
• Support the development of a sustainable healthcare system in China.
RDPAC 2024-2025 Executive Committee
MEMBERSHIP
-
Abbott
www.abbott.com.cn
-
AbbVie
www.abbvie.com.cn
-
Allergan
www.allerganaesthetics.cn
-
ALK
www.alk.net.cn
-
Amgen
www.amgen.cn/en
-
Aspen
www.aspenpharma.cn
-
Astellas
www.astellas.com.cn
-
AstraZeneca
www.astrazeneca.com.cn
-
Bayer
www.bayer.com.cn/en
-
Biogen
www.biogen.cn
-
Boehringer Ingelheim
www.boehringer-ingelheim.cn
-
Bristol Myers Squibb
www.bms.com/cn
-
Chiesi
www.chiesigroup.cn
-
Chugai
www.chugai-pharm.co.jp
-
Daiichi Sankyo
www.daiichisankyo.com.cn
-
Eisai
www.eisai.com.cn
-
Eli Lilly
www.lillychina.com
-
Ethypharm
www.ethypharm.com.cn
-
Ferring
www.ferring.com
-
Gedeon Richter
www.gedeonrichter.com.cn
-
Gilead Sciences
www.gileadchina.cn/en
-
GSK
www.gsk-china.com
-
Helsinn
www.helsinn.com
-
Ipsen
www.ipsen.cn
-
Johnson and Johnson
www.jnj.com.cn
-
Kyowa Kirin
kylinpharma.com
-
LEO Pharma
www.leo-pharma.cn
-
Lundbeck
www.lundbeck.com/cn
-
Menarini
www.menariniapac.com
-
Mayoly
mayoly.com/en/
-
Merck
www.merckgroup.com.cn
-
MSD
www.msdchina.com.cn
-
Mundipharma
cn.mundipharma.com
-
Novartis
www.novartis.com.cn
-
Novo Nordisk
www.novonordisk.com.cn
-
Organon
www.organonchina.com.cn
-
Pfizer
www.pfizer.com.cn/en
-
Ping An-Shionogi
www.pingan-shionogi.cn
-
Roche
www.roche.com.cn
-
Sanofi
www.sanofi.cn
-
Santen
www.santen-china.com.cn
-
Servier
www.servier.com.cn
-
Sumitomo Pharma
en.sumitomo-pharma.com.cn
-
Takeda
www.takeda.com
-
Teva
www.teva.cn
-
UCB
www.ucb.com
-
Zambon
www.zambon.com.cn
Note: the Executive Committee and the member companies are listed in alphabetical order according to the English names of the member companies.
RDPAC CODE
A major requisite for innovation is integrity, which is also the foundation of reputation. Without ethical decision-making, there is no true innovation.
As the first pharmaceutical industry organization in China to attach great importance to compliance, and as a member and an active player of the global pharmaceutical industry association network, RDPAC has continuously strived to reflect the latest standards of international pharmaceutical industry associations, using the Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) as its foundation in doing so. At the same time, RDPAC has kept abreast of the latest requirements of Chinese laws, regulations and policies, and the cutting-edge developments in business practices and compliance controls in China's pharmaceutical industry, providing member companies with the latest and highest standards of compliance based on best practice. Adherence to the RDPAC Code of Practice has also been made a precondition for companies to join RDPAC. Furthermore, RDPAC is supportive of the member companies’ intention to develop and implement their more stringent in-house codes of practice on this basis.
